<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04319965</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A03234-51</org_study_id>
    <nct_id>NCT04319965</nct_id>
  </id_info>
  <brief_title>Complications Related to Transpulmonary Thermodilution</brief_title>
  <acronym>COTRADIL</acronym>
  <official_title>Complications Related to Transpulmonary Thermodilution in the Intensive Care Unit and the Operating Room</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bicetre Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bicetre Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The transpulmonary thermodilution is commonly used in patients with acute circulatory failure
      in the intensive care unit and for monitoring surgical patients at high risk. However, the
      incidence of complications and their risk factors in patients monitored by transpulmonary
      thermodilution has not been completely reported yet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transpulmonary thermodilution (TPTD) is a technique used for haemodynamic monitoring. It
      consists of a monitor device which is connected to two catheters. One is a catheter inserted
      into the superior vena cava (internal jugular or subclavian), which is a standard catheter
      commonly used in patients with acute circulatory failure. The other one is a
      thermistor-tipped arterial catheter, which is inserted through the femoral route (the tip
      stands in the iliac artery), which allows the measurement of blood temperature. Catheters
      designed for the radial, brachial and humeral arteries also exist. TPTD allows the
      computation of cardiac output from the thermodilution curve recorded by the thermistor-tipped
      femoral arterial catheter. As an advanced cardiac output monitoring technique, it provides
      several important haemodynamic variables. It can be used in the intensive care unit (ICU) and
      in the operating room (OR). Two TPTD systems are now on the market. The PiCCO2 system
      (Pulsion Medical Systems, member of the Getinge Group, Feldkirchen, Germany) and the
      VolumeView/EV1000 system (Edwards Lifesciences, Irvine, United States of America). This study
      is designed to investigate the incidence of complications and their risk factors in patients
      monitored by transpulmonary thermodilution.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To describe the incidence of transpulmonary thermodilution related complications</measure>
    <time_frame>At the time of TPTD catheters removal, an average of 7-14 days, depending on the individual situation</time_frame>
    <description>Systematic report of mechanical, haemorragic and infections complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of theoretical risk factors for these complications.</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Systematic report of morphologic characteristics, coagulation, immunity</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Critical Illness</condition>
  <condition>Hemodynamic Instability</condition>
  <condition>Septic Shock</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted in ICU or intermediate care units and in OR, monitoring by TPTD system
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Monitoring by a TPTD system (PiCCO2 or VolumeView/EV1000) already planned or set up

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Monnet, MD.PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical intensive care unit; Bicêtre Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier Monnet, MD.PhD</last_name>
    <phone>331 45 21 35 39</phone>
    <email>xavier.monnet@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bicetre Hospital</name>
      <address>
        <city>Paris</city>
        <state>Val-de-Marne</state>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Monnet, MD. PhD</last_name>
      <phone>331 45 21 35 39</phone>
      <email>xavier.monnet@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Sakka SG, Reuter DA, Perel A. The transpulmonary thermodilution technique. J Clin Monit Comput. 2012 Oct;26(5):347-53. doi: 10.1007/s10877-012-9378-5. Epub 2012 Jul 18. Review.</citation>
    <PMID>22806214</PMID>
  </reference>
  <reference>
    <citation>Monnet X, Teboul JL. Transpulmonary thermodilution: advantages and limits. Crit Care. 2017 Jun 19;21(1):147. doi: 10.1186/s13054-017-1739-5. Review.</citation>
    <PMID>28625165</PMID>
  </reference>
  <reference>
    <citation>Jozwiak M, Teboul JL, Monnet X. Extravascular lung water in critical care: recent advances and clinical applications. Ann Intensive Care. 2015 Dec;5(1):38. doi: 10.1186/s13613-015-0081-9. Epub 2015 Nov 6.</citation>
    <PMID>26546321</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, Rhodes A, Perel A, Martin GS, Della Rocca G, Vallet B, Pinsky MR, Hofer CK, Teboul JL, de Boode WP, Scolletta S, Vieillard-Baron A, De Backer D, Walley KR, Maggiorini M, Singer M. Clinical review: Update on hemodynamic monitoring--a consensus of 16. Crit Care. 2011 Aug 18;15(4):229. doi: 10.1186/cc10291. Review.</citation>
    <PMID>21884645</PMID>
  </reference>
  <reference>
    <citation>Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, Jaeschke R, Mebazaa A, Pinsky MR, Teboul JL, Vincent JL, Rhodes A. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014 Dec;40(12):1795-815. doi: 10.1007/s00134-014-3525-z. Epub 2014 Nov 13.</citation>
    <PMID>25392034</PMID>
  </reference>
  <reference>
    <citation>Belda FJ, Aguilar G, Teboul JL, Pestaña D, Redondo FJ, Malbrain M, Luis JC, Ramasco F, Umgelter A, Wendon J, Kirov M, Fernández-Mondéjar E; PICS Investigators Group. Complications related to less-invasive haemodynamic monitoring. Br J Anaesth. 2011 Apr;106(4):482-6. doi: 10.1093/bja/aeq377. Epub 2010 Dec 26. Review.</citation>
    <PMID>21205627</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bicetre Hospital</investigator_affiliation>
    <investigator_full_name>Xavier Monnet</investigator_full_name>
    <investigator_title>Professor Xavier Monnet MD. PhD.</investigator_title>
  </responsible_party>
  <keyword>Hemodynamic monitoring</keyword>
  <keyword>Transpulmonary Thermodilution</keyword>
  <keyword>Intensive care unite</keyword>
  <keyword>Operating room</keyword>
  <keyword>Complications of catheters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

